RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors
Latest Information Update: 23 Jul 2024
At a glance
- Drugs BMS 986115 (Primary)
- Indications Fibroma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RINGSIDE
- Sponsors Ayala Pharmaceuticals; Immunome
- 14 May 2024 According to an Immunome media release, the company expects to report topline data for RINGSIDE Part B in the second half of 2025. In parallel, Immunome continues to perform additional manufacturing and pharmacology work required to support a new drug application filing for AL102.
- 28 Mar 2024 According to an Ayala Pharmaceuticals media release, company successfully completed an underwritten offering of 11.5M shares priced at $20 per share for gross proceeds of $230.0M in February 2024, providing capital that is expected to support completion of the RINGSIDE trial.
- 28 Mar 2024 According to an Ayala Pharmaceuticals media release, company expects to report topline data for the ongoing Phase 3 RINGSIDE Part B trial of AL102 in the first quarter of 2025.